AngioDynamics (NASDAQ:ANGO) Releases FY 2027 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of -0.290–0.240 for the period, compared to the consensus earnings per share estimate of -0.260. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $337.6 million.

Analysts Set New Price Targets

Several analysts have weighed in on ANGO shares. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.50.

AngioDynamics Trading Down 20.9%

Shares of ANGO stock opened at $11.23 on Friday. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29. The firm’s 50 day moving average is $15.39 and its 200-day moving average is $13.11. The firm has a market capitalization of $472.22 million, a price-to-earnings ratio of -12.91 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities research analysts forecast that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Warren Jr sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.00% of the company’s stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of approximately $80.9 million, up 6.9% year over year and slightly above analyst expectations. The company’s reported loss of $0.04 per share was also better than the consensus estimate of a $0.11 loss. AngioDynamics Fiscal Q1 Earnings Snapshot
• Positive Sentiment: Gross margin expanded to 59.4%, an improvement of 410 basis points from the prior-year quarter. Med Tech sales rose 13.2% to $39.9 million, led by Auryon growth of 14.7% and NanoKnife growth of 29.0%. AngioDynamics Fiscal Q1 Financial Results
• Positive Sentiment: The company received FDA IDE approval for a feasibility study evaluating NanoKnife irreversible electroporation for benign prostatic hyperplasia, potentially expanding the technology’s addressable market. AngioDynamics Reports First-Quarter Sales
• Neutral Sentiment: Management reaffirmed fiscal 2027 revenue guidance of $336 million to $341 million and adjusted EPS guidance of a $0.24 to $0.29 loss. The outlook is broadly consistent with analysts’ expectations, offering limited upside surprise. AngioDynamics Fiscal 2027 Outlook
• Negative Sentiment: AngioDynamics remains unprofitable, with a GAAP net loss of roughly $7.1 million and continued negative margins. Operating cash flow was also negative at $15.3 million, while cash stood at $34.0 million at quarter-end.
• Negative Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. Although Honroth brings industry experience, the leadership change introduces execution uncertainty and likely contributed to the market’s negative reaction. AngioDynamics Announces New CEO

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.